Genmab A/S (NASDAQ:GMAB) Shares Gap Down - What's Next?

Key Points

• Genmab A/S shares experienced a significant decline, gapping down from a previous close of $22.69 to an opening price of $21.36, indicating potential volatility in the stock.
• Despite the drop, analysts have a generally positive outlook, with the stock rated as a "Moderate Buy," and a price target increase from $45 to $46 by Truist Financial.
• The company's latest earnings report showed a net margin of 35.11% and an earnings per share of $0.54, exceeding consensus estimates by $0.15.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $22.69, but opened at $21.36. Genmab A/S shares last traded at $21.46, with a volume of 494,987 shares traded.

Analysts Set New Price Targets

A number of research firms have recently weighed in on GMAB. Wall Street Zen raised Genmab A/S from a "hold" rating to a "buy" rating in a research note on Monday, July 28th. Truist Financial upped their price objective on Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research note on Tuesday, July 8th. One analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $37.80.

Genmab A/S Trading Down 5.6%

The business has a 50-day moving average price of $21.74 and a 200 day moving average price of $20.86. The stock has a market capitalization of $13.75 billion, a P/E ratio of 10.77, a P/E/G ratio of 6.51 and a beta of 0.95.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.39 by $0.15. Genmab A/S had a return on equity of 21.23% and a net margin of 37.53%. The business had revenue of $925.00 million for the quarter, compared to the consensus estimate of $5.77 billion. On average, sell-side analysts predict that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GMAB. JPMorgan Chase & Co. raised its position in Genmab A/S by 3,049.3% during the fourth quarter. JPMorgan Chase & Co. now owns 407,613 shares of the company's stock valued at $8,507,000 after purchasing an additional 394,670 shares during the period. Franklin Resources Inc. raised its holdings in shares of Genmab A/S by 20.4% in the fourth quarter. Franklin Resources Inc. now owns 30,896 shares of the company's stock worth $645,000 after buying an additional 5,233 shares during the period. Russell Investments Group Ltd. raised its holdings in shares of Genmab A/S by 18,959.1% in the fourth quarter. Russell Investments Group Ltd. now owns 510,784 shares of the company's stock worth $10,660,000 after buying an additional 508,104 shares during the period. Cerity Partners LLC raised its holdings in shares of Genmab A/S by 6.8% in the fourth quarter. Cerity Partners LLC now owns 51,264 shares of the company's stock worth $1,070,000 after buying an additional 3,261 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in shares of Genmab A/S in the fourth quarter worth approximately $2,463,000. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.